NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Je nach Börse kann das Aktiensymbol variieren. Zum Beispiel werden Neurometrix-Aktien an der Börse Boerse Stuttgart unter dem Symbol NLZD.STU gehandelt.
Wie viele Mitarbeiter hat Neurometrix?▼
Stand September 04, 2026 hat das Unternehmen 13 Mitarbeitende.
In welchem Sektor ist Neurometrix tätig?▼
Neurometrix ist im Sektor Gesundheit & Wellness tätig.
Wann hat Neurometrix einen Split durchgeführt?▼
Der letzte Aktiensplit von Neurometrix war am November 20, 2019 mit einem Verhältnis von 1:10.
Wo hat Neurometrix seinen Hauptsitz?▼
Der Hauptsitz von Neurometrix befindet sich in Woburn, Vereinigte Staaten.